What is HC Wainwright’s Estimate for SNTI FY2030 Earnings?

Senti Biosciences, Inc. (NASDAQ:SNTI) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Senti Biosciences in a note issued to investors on Friday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.07) for the year. The consensus estimate for Senti Biosciences’ current full-year earnings is ($14.54) per share.

Several other analysts have also recently commented on the company. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday. Chardan Capital boosted their price target on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.00.

Senti Biosciences Price Performance

Shares of SNTI opened at $0.79 on Monday. The business has a 50-day moving average of $0.95 and a 200-day moving average of $1.38. The company has a market capitalization of $20.77 million, a price-to-earnings ratio of -0.25 and a beta of 2.12. Senti Biosciences has a 1 year low of $0.79 and a 1 year high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $1.00 million.

Hedge Funds Weigh In On Senti Biosciences

A number of large investors have recently modified their holdings of SNTI. Jane Street Group LLC acquired a new stake in Senti Biosciences in the 4th quarter valued at $40,000. Virtu Financial LLC acquired a new position in Senti Biosciences during the fourth quarter worth $46,000. Citadel Advisors LLC acquired a new position in Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC lifted its stake in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after buying an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Senti Biosciences in the second quarter valued at $1,883,000. 25.70% of the stock is currently owned by institutional investors.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.